TALEN

TALEN1-ryr1a

ID
ZDB-TALEN-131028-4
Name
TALEN1-ryr1a
Previous Names
  • ryr1a-ex6 TALEN (1)
Target
Target Sequence 1
5' - GGACCATTCACCCTGCAT - 3'
Target Sequence 2
5' - CTGACCTTCTCACCCT - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
z42 ryr1a
Expression
Gene expression in Wild Types + TALEN1-ryr1a
No data available
Phenotype
Phenotype resulting from TALEN1-ryr1a
No data available
Phenotype of all Fish created by or utilizing TALEN1-ryr1a
Phenotype Fish Conditions Figures
somite ryr1a expression decreased amount, abnormal ryr1az42/z42 standard conditions Fig. S5 from Chagovetz et al., 2019
somite ryr1a expression decreased amount, abnormal ryr1az42/z42 standard conditions Fig. S2 from Chagovetz et al., 2019
muscle pioneer decreased amount, abnormal ryr1az42/z42 standard conditions Fig. 2. with image from Chagovetz et al., 2019
slow muscle cell decreased amount, abnormal ryr1az42/z42 standard conditions Fig. 2. with image from Chagovetz et al., 2019
fast muscle cell decreased amount, abnormal ryr1az42/z42 standard conditions Fig. 2. with image from Chagovetz et al., 2019
whole organism dead, abnormal ryr1az42/z42; ryr1bmi340/mi340 standard conditions Figure 3-figure supplement 1 with image from Volpatti et al., 2020
whole organism viability, abnormal ryr1az42/z42; ryr1bmi340/mi340 standard conditions Figure 3-figure supplement 1 with image from Volpatti et al., 2020
whole organism paralysed, abnormal ryr1az42/z42; ryr1bmi340/mi340 control Figure 3-figure supplement 1 with image from Volpatti et al., 2020
whole organism paralysed, abnormal ryr1az42/z42; ryr1bz43/z43 standard conditions Fig. 3 from Chagovetz et al., 2019
slow muscle cell decreased amount, abnormal ryr1az42/z42; ryr3z45/z45 standard conditions Fig. 2. with image from Chagovetz et al., 2019
fast muscle cell decreased amount, abnormal ryr1az42/z42; ryr3z45/z45 standard conditions Fig. 2. with image from Chagovetz et al., 2019
ventral mandibular arch increased width, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 6. with image from Chagovetz et al., 2019
slow muscle cell undulate, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 5. with image from Chagovetz et al., 2019
swimming decreased occurrence, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 5. with image from Chagovetz et al., 2019
ventral mandibular arch decreased length, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 6. with image from Chagovetz et al., 2019
slow muscle cell morphology, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 5. with image from Chagovetz et al., 2019
Meckel's cartilage morphology, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 6. with image from Chagovetz et al., 2019
neural tube ventral region nkx6.1 expression decreased amount, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 control Fig. 2 with image from Klatt Shaw et al., 2018
slow muscle cell ab1-ryr labeling absent, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 1. with image from Chagovetz et al., 2019
slow muscle cell decreased amount, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 control Fig. 1 with image from Klatt Shaw et al., 2018
floor plate nkx2.2a expression decreased amount, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 control Fig. 2 with image from Klatt Shaw et al., 2018
slow muscle cell muscle pioneer decreased amount, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 control Fig. 1 with image from Klatt Shaw et al., 2018
fast muscle cell decreased amount, exacerbated ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 chemical treatment by environment: azumolene sodium Fig. 1 with image from Klatt Shaw et al., 2018
slow muscle cell muscle pioneer decreased amount, exacerbated ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 chemical treatment by environment: azumolene sodium Fig. 1 with image from Klatt Shaw et al., 2018
fast muscle cell decreased amount, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 control Fig. 1 with image from Klatt Shaw et al., 2018
slow muscle cell sarcomere increased size, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 5. with image from Chagovetz et al., 2019
palatoquadrate arch decreased length, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 6. with image from Chagovetz et al., 2019
fast muscle cell ab1-ryr labeling absent, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 1. with image from Chagovetz et al., 2019
slow muscle cell decreased amount, exacerbated ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 chemical treatment by environment: azumolene sodium Fig. 1 with image from Klatt Shaw et al., 2018
palatoquadrate arch increased width, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 6. with image from Chagovetz et al., 2019
somite slow muscle cell increased length, abnormal ryr1az42/z42; ryr1bz43/z43; ryr3z45/z45 standard conditions Fig. 5. with image from Chagovetz et al., 2019
skeletal muscle cell ptch2 expression decreased distribution, abnormal ryr1az42/z42; ryr2az44/z44; ryr3z45/z45 control Fig. 3 with image from Klatt Shaw et al., 2018
skeletal muscle cell ptch2 expression decreased amount, abnormal ryr1az42/z42; ryr2az44/z44; ryr3z45/z45 control Fig. 3 with image from Klatt Shaw et al., 2018
neural tube ventral region ptch2 expression decreased amount, abnormal ryr1az42/z42; ryr2az44/z44; ryr3z45/z45 control Fig. 3 with image from Klatt Shaw et al., 2018
neural tube ventral region ptch2 expression decreased distribution, abnormal ryr1az42/z42; ryr2az44/z44; ryr3z45/z45 control Fig. 3 with image from Klatt Shaw et al., 2018
Citations